Abstract: A process for recovering interferon which comprises contacting a solution containing an interferon produced by the induced cells of human origin with a water-insolubilized sulfated polysaccharide to allow the interferon to be adsorbed on the water-insolubilized sulfated polysaccharide and then selectively eluting the interferon with an aqueous solution of an inorganic salt.

Abstract: New organic dibasic acid half esters of 7-ketocholesterol and of 7-hydroxycholesterol represented by the general formula ##STR1## (wherein R.sub.1 is .dbd.O or --OH and R.sub.2 is a C.sub.1 -C.sub.5 alkylene group or a phenylene group) and physiologically acceptable salts thereof. These compounds are effective as an immunosuppressive or an anti-inflammatory agent.

Abstract: The invention relates to a process for concentrating blood coagulation Factor XIII (Fibrin stabilizing factor) which comprises removing a fraction precipitated at a pH of 6 to 9 in a concentration of 4 to 9% (W/V) of an alkylenoxide polymer or copolymer having a molecular weight of 2,000 to 20,000 from a crude globulin fraction obtained from human placentae by separating in albumin fraction therefrom, and then collecting the fraction precipitated in the concentration of 20 to 30% (W/V) of said polymer or copolymer, thereby obtaining easily said blood coagulation Factor XIII free from pyrogen in good yield.

Abstract: A colony-stimulating factor having definite physical and chemical properties and a function of stimulating activity on human bone marrow cells to proliferate and differentiate, thereby forming granulocyte colonies, is obtained from human urine by concentrating the urine with respect to proteins contained therein by adsorption chromatography with silica gel, salting out with ammonium sulfate and other means, then removing impurities by adsorption on cation exchanger, and further purifying by ion exchanging chromatography on anion exchanger, gel filtrating chromatography with highly crosslinked gels, affinity chromatography with sugar affinitive adsorbents and electrophoresis. This substance is stable in the presence of a stabilizer such as albumin or urinary proteins, against heat-treatment of virus-inactivation and can be used as a leukopenia curative which is precluded from fear of virus-infection.

Abstract: Compounds of the general formula ##STR1## or their salts, esters or amide derivatives; and processes for their preparation. In the formula, R.sub.O represents hydrogen or lower alkyl, R.sub.2 represents hydrogen, halogen or nitro, R.sub.3 represents hydrogen or halogen, and R.sub.4 represents hydrogen or lower alkyl; and when R.sub.O is hydrogen, R.sub.2, R.sub.3 and R.sub.4 are all hydrogens and the group ##STR2## is present at the 2-position. These compounds exhibit superior analgesic and/or anti-inflammatory actions with little gastrointestinal troubles.

Abstract: An aqueous solution of haptoglobin is obtained by subjecting an aqueous solution of .alpha. and .beta.-globulin fractions of human blood plasma to further fractionation by use of ammonium sulfate, collecting fractions precipitated at a concentration between 30% and 40% saturation of ammonium sulfate, contacting a reconstituted aqueous solution of the collected fractions with an anion exchanger to adsorb haptoglobin on said anion exchanger, selectively eluting the haptoglobin from the anion exchanger, and then concentrating the resulting aqueous eluate solution. The aqueous solution of haptoglobin is subjected to heat treatment in the presence of a selected stabilizing agent for inactivating hepatitis B virus at an optional step of the process.The thus obtained aqueous solution of haptoglobin has less than 10% hypotensive activity, highly stable during storage, and free from the risk of hepatitis B virus infection.

Abstract: Because of its large hemoglobin-binding capacity, high physical strength, and ability to be reused on regeneration, the active haptoglobin fixed and insolubilized by embedding into or by chemical interlinking with fibrin is useful for absorbing and removing free hemoglobin liberated in the circulating blood plasma when it is included in an extracorporeal blood circulation system such as an artificial cardiopulmonary system.

Abstract: Hepatitis B surface antigen particles composed of single polypeptide subunits having a molecular weight of about 55,000 dalton are prepared by heating hepatitis B surface antigen in isotonic sodium chloride solution at about neutral pH containing a surfactant capable of delipidation such as alkali-metal salts of bile acids or of lauroylsarcosinic acid, or poloxyethylene alkylphenol containing an average oxyethylene of 7 to 10 molecules, or polyoxyethylene sorbitan monoalkylester containing an average oxyethylene of 20 molecules.A uniform hepatitis B surface antigen particle thus obtained has a spherical form 18 to 22 nm in diameter with an empty core, a molecular weight of about 2,200,000 dalton, and the characteristic of low toxicity.This hepatitis B surface antigen particle is useful for the preparation of vaccines, as a standard antigen reagent for testing hepatitis B surface antigen and the antibody, and as an antigen for immunizing animals to obtain a highly specific and strong antibody.

Abstract: An aqueous solution of haptoglobin is obtained by subjecting an aqueous solution of .alpha. and .beta.-globulin fractions of human blood plasma to further fractionation by use of ammonium sulfate, collecting fractions precipitated at a concentration between 30% and 40% saturation of ammonium sulfate, contacting a reconstituted aqueous solution of the collected fractions with an anion exchanger to adsorb haptoglobin on said anion exchanger, selectively eluting the haptoglobin from the anion exchanger, and then concentrating the resulting aqueous eluate solution. The aqueous solution of haptoglobin is subjected to heat treatment in the presence of a selected stabilizing agent for inactivating hepatitis B virus at an optional step of the process.The thus obtained aqueous solution of haptoglobin has less than 10% hypotensive activity, highly stable during storage, and free from the risk of hepatitis B virus infection.

Abstract: Highly purified urokinase is obtained in a high yield by adsorbing urokinase from an aqueous crude urokuinase solution including human urine at a pH of about 4.0 to about 7.0 on a water-insoluble polysaccharide containing agarose and agaropectin, for example, agar and Sepharose, and by eluting urokinase with an alkaline solution (pH of about 8 to 11) or concentrated salt solution.